Public gets update on cannabis program

Public gets update on cannabis program


The County Dept. of Planning and Development Services (PDS) held a webinar June 25 on its proposed Socially Equitable Cannabis Program, that included a summary of public comments and an update.
County staff was led by Dara Elkurdi, long range planner. Given that this is a menu where you can order anything you wants, as long as it’s chicken, there was no Q&A or comments taken.
“This is not a debate about the legalization of cannabis,” said Elkurdi. She urged those wanting to weigh in to contact elected representatives or send comments to the Board of Supervisors.
The supervisors are likely to vote on the program before the end of this year, she said.
The supervisors directed staff in January 2021 to develop the Socially Equitable Cannabis Program, “intended to establish safe legal access to cannabis along with an equitable path to cannabis-related business opportunities in our unincorporated county.”
It focuses on: regulatory requirements, environmental impact considerations, a licensing and permitting framework and support for equitable access to business related opportunities.
Regulatory requirements concern revisions to the County’s current regulations to allow for new and expanded commercial cannabis businesses in the unincorporated county. Including revisions to the County’s regulatory code and zoning ordinance to establish where and how cannabis businesses can operate.
Second is analysis of potential impacts to the environment from the proposed program. Part of this analysis is identifying ways to reduce those impacts. Those efforts are included in the Environmental Impact Report.
They are also developing structures and procedures for issuing licenses and other permits to run a cannabis business.
The final component focuses on providing support to eligible applicants to successfully establish or gain employment and a cannabis business.
“This include efforts to address the adverse impacts that cannabis criminalization had on people and their communities,” said Elkurdi. That is being led by the County’s Office Of Equity And Racial Justice—through the Social Equity Program.
Elkurdi reported on comments received during the public review period, January 30, 2025 —March 31, 2025 on the draft EIR and the draft regulatory code and zoning ordinance.
Currently the staff is reviewing all the public feedback received during the public review period.
“This input is really going to help us shape and finalize that program in alignment with all of these stakeholder perspectives that we had and the final EIR—along with responses with those comments and the updated ordinances—are all going to be made available ahead of the public hearings around fall of this year,” said Elkurdi.
The program will probably go to the Planning Commission for its recommendation in the winter of 2025-26, although dates are fluid.
She noted that the webinar she was holding was not mandated under the California Environmental Quality Act (CEQA), but in response to requests to see some of the responses the County had gotten.
“We are holding this webinar because we want to be responsive to those requests and to provide some transparency on the kinds of comments that we received,” she said.
Since the board gave direction to staff in January 2021 the County has conducted 258 outreach meetings, including 33 county-hosted public outreach meetings, 31 meetings with county technical advisory and stakeholder groups, 49 meetings with community planning and sponsor groups, 28 meetings with local tribes, 51 coordination meetings with regulatory and government agencies and 67 other individual and group meetings.
Staff also attends cannabis meetings hosted by the Department of Cannabis Control or other advisory groups or forums to learn about other cannabis issues throughout the state.
Public feedback has helped shape the development of the program.
The County originally started with proposed measures for the zoning ordinance and regulatory code and then took these measures to public outreach events. After each outreach event they reviewed the comments.
“They were really instrumental in helping us identify key concerns and areas for improvement,” she said. “We were able to reach a really diverse group of stakeholders— which has given us a good range of viewpoints for us to consider.”
They used to feedback to prepare revision to the draft ordinances and EIR that had been released.
“We are currently reviewing those comments and preparing responses which will all be included in the final EIR.” She added, “I want to make it clear we don’t just incorporate the feedback we receive our public outreach events or that we received during that EIR comment period. We have received hundreds of other comments via e-mail and phone and letters —which have all also helped shape the program.”
Staffer Chen Levy said public they included comments from California Department of Fish and Wildlife, San Diego Air Pollution Control District, San Diego Regional Water Quality Control Board, organizations in fields such as public health, social equity environmental groups, community organizations, school districts and community planning and sponsor groups. Plus comments from individuals such as residents of the unincorporated area.
They divided comments into two categories, environmental or non-environmental. “Although these non-EIR related comments don’t relate to the EIR directly, they are still considered in the broader development process of the program—just not within the framework of the EIR,” said Levy.
Most comments expressed support for a specific alternative in the draft EIR either for Alt. 2—which follows state regulations and Alt 4 which requires 1,000 feet buffer from expanded sensitive uses and prohibits outdoor cultivation.
Stakeholders were concerned about environmental impacts and how the project could affect wildlife and other agricultural operations and contribute to air pollution, light pollution and water usage.
Comments on cannabis odors ranged from general concerns about odors from cannabis cultivation to more specific concerns about odors emitting from outdoor cultivation.
While not considered part of the EIR, “there non-EIR topics are still valuable. We will consider them in the broader development process of the program. Such as in the ordinances and permitting and licensing systems,” said Levy.
Some comments related more to law enforcement or code enforcement. Others were more appropriate for the Sheriff’s Office or Behavioral Health Services.
“However, staff does coordinate with these parties on a regular basis to ensure implementation of the cannabis program is connected across the county.”
Commenters “expressed a range of public health concerns related to cannabis operations,” said Levy.
They raised concerns about facilities located near schools and youth spaces and exposure to second hand smoke from lounges and events.
Other comments raised concerns over contamination of cannabis products with pesticides and banned chemicals. Plus concerns over the ability to test cannabis products for pesticides or contaminants and the transparency of the results to the consumers.
Some were concerned about having sufficient code enforcement officers and law enforcement to address multiple potential complaints relating to odor noise and other health and safety concerns. As well as crime and theft.
“Lastly we also received comments on the proposed ordinance changes separate from the environmental analysis,” said Levy.
Comments relating to the drafting zoning ordinance and regulatory code, included selection of sensitive uses and buffer distances and recommendations to introduce new sensitive uses like residential zones.
“We also heard feedback that certain sensitive uses like preserves and religious assemblies should be removed,” said Levy. “Some commenters noted that the sensitive uses seemed to only address those who live in more urban areas and provide little protection for those living in rural areas.”



Source link

State orders cannabis testing lab to suspend operations | Boston

State orders cannabis testing lab to suspend operations | Boston


BOSTON — Cannabis regulators have ordered one of the state’s independent testing labs to suspend operations, alleging a “pattern of failing to accurately report” marijuana test results and “an intentional effort to conceal those failing results.”

The Cannabis Control Commission said an investigation led by its new Investigations & Enforcement Taskforce determined that Tyngsborough-based Assured Testing Laboratories was not accurately reporting the results of tests for yeast and mold in cannabis to the commission or to Metrc, the seed-to-sale tracking system CCC licensees must use.

Cannabis samples tested by Assured were 90% less likely to fail because of the presence of yeast and mold than the industry average, the CCC said. Regulators alleged the lab’s operation “undermines the Commission’s ability to ensure compliance, and posed an immediate or serious threat to public health, safety, or welfare.”

“The Cannabis Control Commission (Commission) remains vigilant in its efforts to ensure consumers and patients have access to fairly and accurately tested products in the marketplace,” a CCC spokesperson said. The statement added that the investigation was “focused on improving product testing as part of the Commission’s mission to oversee a safe, equitable cannabis marketplace in Massachusetts.”

The license suspension order dated June 30 requires the lab to cease all operations by Friday, a delay in the order’s effective date that CCC officials said is to allow the company time to wind down operations and complete any open testing orders.

Reached by phone Wednesday morning, a person who identified himself as the lab director at Assured said the company was in the process of preparing a statement and would have no comment until then. The company is entitled to appeal the suspension within 21 days.

The CCC said Assured’s lab tested 22,531 marijuana products from 61 different marijuana establishments between April 2024 and April 2025, roughly 25% of the cannabis yeast and mold tests conducted in the state during that time.

Results that Assured submitted to Metrc showed that just 10 samples out of 17,565 failed for containing total yeast and mold in excess of state limits, a 0.05% failure rate. The CCC said the state’s average yeast and mold fail rate is 4.5% of samples.

Regulators at the CCC have zeroed in on issues in the testing space, including with a November public listening session to hear concerns from independent testing labs and the creation of its investigatory task force. The CCC said it has been in regular contact with the 11 independent testing labs that operate in Massachusetts since the November meeting.

The CCC is now also requiring testing labs to upload a digital certificate of analysis after every product test to document the methods used to ensure products are in compliance with state regulations, and is eliminating the past practice of allowing marijuana companies to select more than one independent testing lab to perform required testing.



Source link

Cannabis Isn’t Bringing In the Green in Santa Barbara County

Cannabis Isn’t Bringing In the Green in Santa Barbara County


Santa Barbara County collected less than a million dollars from the cannabis industry in the third quarter of the fiscal year, coming in below the expected projections in tax revenues for permitting, licensing, and enforcement for Fiscal Year 2024-25, according to a report released to the Board of Supervisors Tuesday.

Cannabis Program Manager Carmela Beck presented the updated figures, which totaled about $870,800 in taxes from 31 different operations in the county. Eighteen more operators did not harvest this season and reported no gross revenues from January to March. So far, the county has collected $3.9 million in Fiscal Year 2024-25, with the bulk of revenues coming from indoor cultivation (greenhouses, enclosed buildings, and operations with artificial lighting) with about $505,000 from this quarter and a total of $2 million this year.

At the current rate, the county is projected to reach about $5.4 million in cannabis tax revenues this fiscal year, more than a half-million short of the originally projected total of more than $6 million. 

In addition to tax revenues, the county’s enforcement activities resulted in more than $3,600 worth of dried cannabis products and $24,000 more in processed products, with more than 1,500 illegal vapes, edibles, and pre-rolls seized by the Sheriff’s Office.

Next month, the county will likely be approving ordinance amendments to reduce the allowed acreage for cannabis grows. County staff are also working with 29 operators to get them up to date with recently adopted odor abatement requirements, which will require new systems to be in place and installed by March 31, 2026.



Source link

Maryland’s first cannabis incubator to change site after pushback

Maryland’s first cannabis incubator to change site after pushback


Gov. Wes Moore changed his mind.

The governor on Wednesday said that Catonsville armory will no longer be the site of the state’s first cannabis incubator after some complaints and confusion by community members.

“Upon further review of this project … I have concluded that the state should explore new options for its location,” Moore said in a statement about the program, which is designed to promote Black-and-brown-owned marijuana businesses.

The decision comes one week after The Baltimore Banner published an article where some Catonsville residents said they were frustrated the armory was chosen without community consultation because the site sits directly across from Catonsville Elementary School and a local day care.

The Baltimore Banner thanks its sponsors. Become one.

Josh Jackson, a father-of-two who started a petition on Change.org to demand officials reconsider using the Catonsville armory, praised the move.

“Wow, that’s fantastic,” he said. “I’m glad (Moore’s) kind of speaking from the top and taking leadership of the whole issue, which is what we were looking for.

“It gives you a little bit of hope,” Jackson added.

Catonsville resident Josh Jackson. (Kaitlin Newman/The Baltimore Banner)

The Maryland Economic Development Corporation submitted a report to Moore and the state legislature in December 2023 identifying 37 sites across the state to be considered for the project. The Catonsville armory was not among them.

Still, the General Assembly voted to commit $7 million out of the 2025 and 2026 state budgets to fund the program at the Baltimore County location.

The Baltimore Banner thanks its sponsors. Become one.

The governor’s deputy chief of staff Manny Welsh previously told The Banner the Catonsville site was moving forward and that Moore and the state legislature were “aligned.”

The incubator project will house up to 110 cannabis micro-businesses that store or process marijuana into products like vapes or edibles.

Moore said that MEDCO, the Maryland Cannabis Administration and the Maryland Department of General Services will start this new selection process immediately and consult all community members involved.

“I have instructed the agencies to identify locations that are not within close proximity to residential communities and schools,” Moore said.

The state’s general services department will retain control of the Catonsville armory, the governor said, and move to properly demilitarize, salvage and either transfer, donate or sell the site to the public.





Source link

Cannabis Workers at Columbia Care Stay Determined, Ratify First Contract With UFCW Local 152

Cannabis Workers at Columbia Care Stay Determined, Ratify First Contract With UFCW Local 152


EGG HARBOR TOWNSHIP, N.J., July 02, 2025–(BUSINESS WIRE)–UFCW Local 152 members at the Columbia Care cannabis cultivation facility in Vineland, N.J. ratified their first union contract, capping off a years-long journey of determination and persistence.

Members in the cultivation department voted overwhelmingly to accept their contract, which delivers on many of the priorities workers had when they first sought union representation back in November of 2022.

“These workers never gave up despite an atrociously long road to their first contract,” UFCW Local 152 President Daniel Ross, Jr. said. “Through all the delays brought on by the employer, Local 152 stood with these workers to ensure they had their seat at the table and they won their first contract.”

Columbia Care workers finally organized with Local 152 in 2023 after first expressing interest in union representation the year prior. Local 152 was forced to engage in a protracted legal process for recognition as the employer opposed Local 152’s effort to have the New Jersey State Board of Mediation certify the bargaining unit. Columbia Care argued that the employees may or may have not been “agricultural workers” under federal labor law. Local 152 was forced to seek a determination from the National Labor Relations Board in an unnecessary and lengthy process.

“This was a classic anti-union stall tactic meant to stifle workers’ momentum to organize,” President Ross said. The National Relations Board eventually found that the employees were not under its jurisdiction. New Jersey law and regulations in the cannabis industry permits all cannabis workers to organize regardless of whether federal labor laws apply. The New Jersey Board of Mediation eventually certified the unit, finally allowing these workers the opportunity to negotiate with their employer.

This unnecessary delay in negotiations spurred Local 152 to pursue NJ Bill A4182, which received bipartisan sponsorship. If approved, A4182 will simply close this loophole and clearly afford cultivation workers in New Jersey the same rights to the organizing process as all other workers who are not protected by federal labor law regardless of whether a Labor Peace Agreement is in effect. A4182 passed the final stage of approval by the New Jersey Assembly on June 30 with bipartisan support. Its Senate counterpart, S3139, is now awaiting a vote from the Senate Judiciary Committee.

The first contract accepted on June 23, 2025, provides for substantial retroactive wage increases for all members. This wage increase now brings their wages to industry-leading levels above their non-union counterparts. The agreement also provides for 100% employer-paid ancillary benefits through the union’s Health & Welfare Fund. Valuable benefits such as prepaid legal services, life insurance and vision care were negotiated at no cost to the workers, in addition to all the protections and guarantees found in the four corners of a bona fide labor agreement.



Source link

Virginia GOP Governor Vetoes Recreational Marijuana Sales Legalization Plan

Congressional Cannabis Caucus still hasn’t met this year (Newsletter: July 2, 2025)


VA marijuana commission to shape legal sales; FL gov signs cannabis patient punishments; PA cannabis bill filed; DE legal sales launch date

Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going.

Join us at https://www.patreon.com/marijuanamoment

/ TOP THINGS TO KNOW

Rep. Ilhan Omar (D-MN), a co-chair of the Congressional Cannabis Caucus, told Marijuana Moment that the group still hasn’t held a meeting during the current legislative session—with one-quarter of the 119th Congress now already elapsed.

The new Virginia Joint Commission to Oversee the Transition of the Commonwealth into a Retail Cannabis Market will hold its first meeting next week to begin work preparing the state to legalize recreational marijuana sales after this year’s gubernatorial election.

Florida Gov. Ron DeSantis (R) signed a bill to revoke medical cannabis patient and caregiver registrations from anyone convicted of certain drug crimes.

Bipartisan Pennsylvania senators filed a new bill to create a Cannabis Control Board to oversee the existing medical marijuana program and that could also oversee the adult-use market if broader legalization is enacted.

The Delaware Office of the Marijuana Commissioner announced that recreational cannabis sales will begin on August 1, with Gov. Matt Meyer (D) saying the “new industry will generate critical revenue to strengthen our schools, infrastructure and public health systems, while creating real opportunities for entrepreneurs.”

Americans for Safe Access’s Steph Sherer argues in a new Marijuana Moment op-ed that President Donald Trump’s proposal to delete a federal medical cannabis rider from spending legislation “reveals not only the fragility of patient protections but also exposes Congress’s failure to fulfill its promise” to patients.

Nebraska Gov. Jim Pillen (R) approved emergency medical cannabis rules allowing regulators to begin accepting license applications but blocking patients from accessing marijuana flower, infused food or drinks and any products administered by smoking or vaping.

The New Mexico legislature’s Interim Courts and Criminal Justice Committee held a hearing on cannabis regulators’ efforts to step up enforcement against illicit operations.

/ FEDERAL

Former Drug Enforcement Administration Administrator Derek Maltz tweeted about the “dangerous truth about marijuana advocates don’t want you to know,” pointing to research about its alleged harms and saying that “Chinese criminal networks that are running grow operations all over the country and spraying Chinese pesticides on the plants.”

Rep. Dan Crenshaw (R-TX) said that Health and Human Services Secretary Robert F. Kennedy Jr.’s support for psychedelics therapy is “helping to mainstream what could be a groundbreaking shift in mental health.”

Rep. Brian Mast (R-FL) published a blog post about legislation to increase military veterans’ access to medical cannabis.

Rep. Tom Barrett (R-MI) tweeted, “Great news! → The House passed legislation this week to support our military and veteran community, including critical funding I fought and secure for:…  ✅ Breakthrough PTSD psychedelic treatment… We stand with those who served. 🇺🇸”

The House bill to designate psychedelic innovative therapies centers of excellence got one new cosponsor for a total of nine.

/ STATES

Ohio Gov. Mike DeWine (R) used a line-item veto to reject budget provisions to change the marijuana tax structure.

Colorado’s attorney general announced a settlement that permanently bars a company that allegedly marketed marijuana products as federally legal industrial hemp from participating in the state’s cannabis industry.

The Iowa Supreme Court upheld the conviction of a man who was carrying both marijuana and a pistol in his car.

An Alabama judge rejected a request for a temporary restraining order against certain parts of the state’s hemp product restriction law.

A new Idaho mandatory minimum fine for marijuana possession took effect this week.

A California marijuana tax increase took effect on Tuesday.

A Minnesota law to increase in marijuana taxes took effect on Tuesday.

Utah regulators are accepting applications for a new medical cannabis pharmacy license.

Massachusetts regulators issued an order shutting down a cannabis testing lab over alleged violations.

Vermont regulators said errors with a cannabis inventory tracking form have been fixed.


Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.


Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

/ LOCAL

A judge declined Waterbury, Connecticut officials’ request to issue a contempt citation against a former firefighter who is contesting his firing over medical cannabis use.

/ INTERNATIONAL

The UK solicitor general said in response to a lawmaker’s question that the government has no plans to pursue opening safe drug consumption facilities.

/ SCIENCE & HEALTH

A study found that “CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma.”

A review concluded that “the evidence supports psychedelic-assisted therapy as a viable option for PTSD treatment, particularly MDMA.”

/ BUSINESS

Trulieve Cannabis Corp. filed a shelf registration statement to register a base shelf prospectus, but said it has no immediate plans to offer or sell any securities under this shelf registration.

TerrAscend Corp. is exiting the Michigan market.

atai Life Sciences and Beckley Psytech Limited announced positive topline results from a Phase 2b clinical trial on efficacy and safety of a single dose of 5-MeO-DMT benzoate in patients with treatment-resistant depression.

/ CULTURE

Mike Tyson discussed his push to get the Trump administration to embrace marijuana reform.

Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

U.S. Lingerie Market Worth $34.64 Billion by 2030: Competitive Analysis of Key Players - L Brands, Victoria's Secret Stores & Co., Honey Birdette, Hanesbrands, American Eagle Outfitters and More

Cannabis Pharmaceuticals Business Analysis Report 202s |


Dublin, July 02, 2025 (GLOBE NEWSWIRE) — The “Cannabis Pharmaceuticals – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The global market for Cannabis Pharmaceuticals was estimated at US$5.2 Billion in 2024 and is projected to reach US$72.7 Billion by 2030, growing at a CAGR of 55.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Cannabis-based pharmaceuticals are emerging as a transformative segment within the global healthcare industry, driven by increasing scientific validation of cannabinoids for medical applications. The legalization of medical cannabis in numerous countries has fueled research and development (R&D) efforts, leading to the approval of cannabis-derived drugs for conditions such as epilepsy, multiple sclerosis, and chronic pain. Additionally, shifting regulatory frameworks and growing physician acceptance are paving the way for cannabis-based formulations to be integrated into mainstream healthcare.

What Are the Key Drivers Behind the Growth of the Cannabis Pharmaceuticals Market?

The growth in the cannabis pharmaceuticals market is driven by several factors, including expanding medical cannabis legalization, increased R&D investment, and growing patient demand for alternative treatments. Regulatory approvals for cannabis-based drugs in North America and Europe have legitimized the sector, encouraging pharmaceutical companies to develop new formulations. The opioid crisis has also contributed to the demand for non-addictive pain management solutions, positioning cannabis as a viable alternative.

Additionally, advancements in drug delivery systems and precision dosing are improving the efficacy of cannabis-based medications, further accelerating market growth. As global healthcare systems continue to recognize the benefits of medical cannabis, the pharmaceutical cannabis sector is poised for significant expansion.

How Are Advancements in Cannabis Research Expanding Pharmaceutical Applications?

Ongoing clinical research has uncovered the therapeutic potential of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC), leading to the development of prescription cannabis-based drugs. Pharmaceutical companies are investing in cannabinoid extraction and formulation technologies to enhance bioavailability, stability, and targeted delivery.

Advances in nanotechnology and encapsulation methods are improving the efficacy of oral, transdermal, and inhalable cannabis medications. Additionally, the exploration of minor cannabinoids such as cannabigerol (CBG) and cannabinol (CBN) is expanding the therapeutic scope of cannabis pharmaceuticals, potentially leading to new treatments for neurodegenerative diseases, anxiety disorders, and autoimmune conditions.

Which Therapeutic Areas Are Driving the Demand for Cannabis Pharmaceuticals?

The primary demand for cannabis-based pharmaceuticals comes from patients suffering from chronic pain, neurological disorders, and mental health conditions. Epidiolex, a CBD-based drug, has gained FDA approval for treating rare forms of epilepsy, while Sativex, an oral spray containing THC and CBD, is widely used for multiple sclerosis-related spasticity.

The growing acceptance of cannabis for pain management is leading to its adoption as an alternative to opioids, particularly for cancer and arthritis patients. Additionally, ongoing research into cannabis-based treatments for anxiety, PTSD, and sleep disorders is expanding the potential applications of cannabis pharmaceuticals.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., Aphria Inc., Aurora Cannabis Inc., Bausch Health Companies Inc., Canopy Growth Corporation and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Sativex Brand segment, which is expected to reach US$52.6 Billion by 2030 with a CAGR of a 60.1%. The Epidiolex Brand segment is also set to grow at 49.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.4 Billion in 2024, and China, forecasted to grow at an impressive 51.8% CAGR to reach $10.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Scope of Study:

  • Segments: Brand (Sativex Brand, Epidiolex Brand, Other Brands)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Attributes:

Report Attribute Details
No. of Pages 116
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $5.2 Billion
Forecasted Market Value (USD) by 2030 $72.7 Billion
Compound Annual Growth Rate 55.1%
Regions Covered Global

Key Topics Covered:

MARKET OVERVIEW

  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Cannabis Pharmaceuticals – Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

  • Growing Clinical Research Supporting Therapeutic Use of Cannabinoids
  • Rising Acceptance of Cannabis-Derived Pharmaceuticals in Mainstream Medicine
  • Expansion of Prescription-Based Cannabis Products Driving Market Maturity
  • Advancements in Formulation Science Improving Bioavailability and Efficacy
  • Increased Investment From Pharmaceutical Companies Accelerating Drug Development
  • Emergence of Rare Cannabinoids Creating Opportunities for Niche Therapies
  • Rising Demand for Chronic Pain and Neurological Disorder Treatments
  • Integration of Cannabis Into Palliative and Cancer Care Expanding Patient Base
  • Development of GMP-Compliant Manufacturing Facilities Elevating Product Standards
  • Advancements in Drug Delivery Systems Enhancing Patient Compliance
  • Consumer Shift Toward Plant-Based Medicine Driving Market Growth
  • Increasing Healthcare Professional Education Enhancing Prescribing Confidence
  • Digital Health Platforms Facilitating Cannabis-Based Treatment Accessibility
  • Growth in International Medical Cannabis Programs Supporting Export Markets
  • Focus on Standardized Dosing and Consistency Building Trust in Pharmaceutical Cannabis

FOCUS ON SELECT PLAYERS:Some of the 48 companies featured in this Cannabis Pharmaceuticals market report

  • AbbVie Inc.
  • Aphria Inc.
  • Aurora Cannabis Inc.
  • Bausch Health Companies Inc.
  • Canopy Growth Corporation
  • Cresco Labs Inc.
  • Cronos Group Inc.
  • Curaleaf Holdings, Inc.
  • Green Thumb Industries Inc.
  • GW Pharmaceuticals
  • Harvest Health & Recreation Inc.
  • Hexo Corp.
  • Insys Therapeutics, Inc.
  • Jazz Pharmaceuticals plc
  • MedReleaf Corp.
  • Organigram Holdings Inc.
  • Sundial Growers Inc.
  • Tilray Brands, Inc.
  • Trulieve Cannabis Corp.
  • VIVO Cannabis Inc.

For more information about this report visit https://www.researchandmarkets.com/r/hxhen

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


            



Source link

Applications open for a potential third cannabis storefront in San Luis Obispo

Applications open for a potential third cannabis storefront in San Luis Obispo


The application period for commercial cannabis operations opened July 1 in the city of San Luis Obispo. This means a third cannabis store could open within the city.

“The city does have a three-permit cap that applies only to retail storefronts,” said Ivana Gomez, the San Luis Obispo cannabis business coordinator.

Currently, two of the three permits are already in use by Megan’s Organic Market and SLO Cal Roots.

“As a local operator here, we’re all SLO Cal Roots thrives off competitions, so we’re not necessarily afraid of that,” said Austen Connella, the owner of SLO CAL ROOTS. “But the industry overall has been struggling.”

“It’s not the most ideal timing since we’re in a statewide industry downturn right now,” said Megan Souza, the owner of Megan’s Organic Market.

The city is accepting applications through July 31, and if a permit is issued, there are rules on where it can be located.

“There are requirements for retail store fronts, including land use and operational requirements,” said Gomez. “So land use-wise, retail storefronts are required to be in retail commercial zones or service commercial zones, as well as are required to be located within what we call cannabis business overlay zones, which are designated areas in the city where all cannabis businesses are located.”

The two current cannabis dispensaries in the city are working on getting an amendment to their current permits that will allow deliveries, to help them compete with other dispensaries across the Central Coast.

“We’re hoping to launch in just a matter of weeks, actually,” said Souza, “We’re so excited to be able to make it more convenient for our customers who live here in SLO but also better serve our customers who live outside the SLO.”

During this application period, applications are also being accepted for cultivation, delivery-only retail, manufacturing, testing labs, and distribution.

You can find more information on the city’s website.





Source link

Question of the Bay: How will the new excise tax on cannabis purchases impact dispensaries?

Question of the Bay: How will the new excise tax on cannabis purchases impact dispensaries?


Tax on all cannabis purchases in California increased by four percent on Tuesday.

When Marijuana was first legalized in 2016, California voters also approved two taxes for consumers: a 15 percent retail tax and a four percent cultivation tax. But as the industry struggled to stay afloat, lawmakers repealed the second tax for three years. On Tuesday, that pause expired, increasing taxes to nearly 20 percent for all cannabis purchases.

So, to see how dispensaries are impacted by this new tax, I went to Barbary Coast Dispensary and Smoke Lounge down on Mission Street.

It’s as if you’re walking into any downtown bar with a saloon feel. At the back, around the corner is a small red room with plush walls and floors and two red pool tables. Turn one more corner through double doors and find yourself in a lounge with dimly-lit booths for intimate smoking and the smell of fresh marijuana in the air.

Manager Bridget Awesome, said that she could foresee some customers deciding not to go dispensaries anymore.

Awesome said, “We definitely have some customers who will see after tax prices and then be like, ‘maybe I should just go to my homie.’ and I’m like ‘uhhhh it’s actually more controlled here, you actually know what you’re getting,’ it’s different.”

Budtender Sam Salzeider had a different take. He said, “ It’s a few extra bucks here and there. Do people feel it? Yes, they do. Do I think they’re gonna freak out and never come back? Probably not.”

The money from the tax primarily supports childcare services, environmental efforts and law enforcement programs.

But it could go away once again. The Assembly passed a bill at the start of June to revert the tax back to 15 percent until 2030. Now it goes to the Senate. The next hearing is on July 9.





Source link

Nebraska's Pillen OKs Emergency Medical Cannabis Regulations, Applications Now Sought | Community

Nebraska’s Pillen OKs Emergency Medical Cannabis Regulations, Applications Now Sought | Community


LINCOLN, Neb. — Nebraska Gov. Jim Pillen has officially approved emergency rules and regulations for a regulatory commission to begin licensing medical cannabis establishments no later than Oct. 1.

The regulations had to go into effect Tuesday, based on deadlines overwhelmingly imposed by voters last November when Nebraskans legalized medical cannabis up to 5 ounces with any health care practitioner’s recommendation. Voters also approved a new Nebraska Medical Cannabis Commission to have the “exclusive” power to regulate the new medicine.



Source link